The Latest Breaking News from Novartis

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Teva stock neared a profit-taking zone Wednesday, while GSK stock bounded briefly out of a chase zone on strong fourth-quarter performances for both.

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

Novartis is closing in on a takeover of Cytokinetics, the Wall Street Journal reported Monday, leading CYTK stock to soar in afternoon action.

As biotech stocks boom on a strong 2024 outlook following a rough two years, the XBI ETF launches a fresh breakout.

Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.